Therapeutic benefit of benfluorex in type II diabetic patients treated with sulfonylureas

Journal of Diabetes and its Complications

Volumn 10, Issue 5, 1996, Pages 267-273

  Stucci, Nicola ^a,c   De Gregoris, Patrizio ^b   Lavielle, Rodolphe ^b   Tomasi, Franco ^a  

^a S ANNA HOSPITAL   (Italy)

^b Istituto di Ricerca Servier   (Italy)

^c Dept of Diabet and Metab Diseases ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENFLUOREX; C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SULFONYLUREA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0030578902     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/1056-8727(96)00042-6     Document Type: Article

References (22)

1. 1. Lebovitz HE: Oral antidiabetic agents, in Kahn CR, Weir GC (eds), Joslin's Diabetes Mellitus, 13th ed. Malvern, Lea and Febiger, 1994, pp. 508-529.
2. 2. Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D: Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care 9:129-133, 1986.
3. 3. Groop L, Eriksson J, Schafin C, Ahola A: Does secondary oral failure represent slowly evolving type I diabetes?, in Cameron D, Colagiuri S, Heding L (eds), Non-Insulin-Dependent Diabetes Mellitus. Hong-Kong, Excerpta Medica, 1989, pp. 48-51.
4. 4. Berger, W: Incidence of severe side effects during therapy with sulfonylureas and biguanides. Horm Metab Res 15 (suppl): 111-115, 1985.
5. 5. DeFronzo RA, Goodman AM: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995.
6. 6. Ghis MP, Verando P, Negrel R, Ailhaud G: Utilization of glucose and palmitate during adipose conversion of OB17 cells. Modulation by hypolipidemic drugs. J Pharmacol 15:17-25, 1984.
7. 7. Brindley DN, Hales P, Al-Sieni AII, Russell JC: Decreased serum lipids, serum insulin and triacylglycerol synthesis in adipose tissue of JCR:LA-corpulent rats treated with benfluorex. Biochim Biophys Acta 1085:119-125, 1991.
8. 8. Lacour F, Espinal J, Arnaud O, Duhault J: Improvement in glucose tolerance of insulin resistant rats after chronic or acute administration of benfluorex. Life Sci 53:1525-1529, 1993.
9. 9. Portha B, Serradas P, Bailbe D, Blondel O, Picarel F: Effect of benfluorex on insulin secretion and insulin action in streptozocin-diabetic rats. Diabetes Metab Rev 9 (suppl 1): 57S-63S, 1993.
10. 123 with liver receptors in fa/fa Zucker rats. Diabetes Metab Rev 9 (suppl 1): 73S-79S, 1993.
11. 11. Storlien LH, Pan DA, Kusunoki M, Cooney GJ: Effects of benfluorex on in vivo patterns of insulin resistance induced by diets rich in fat or fructose. Diabetes Metab Rev 9 (suppl 1): 65S-72S, 1993.
12. 12. De Feo P, Lavielle R, De Gregoris P, Bolli GB: Anti-hyperglycaemic mechanisms of benfluorex in type 2 diabetes mellitus. Diabetes Metab Rev 9 (suppl 1): 35S-41S, 1993.
13. 13. Riccio A, Vigili de Kreutzenberg M, Dorella M, Da Tos V, De Biasi L, Marescotti MC, Tiengo A, Del Prato S: Mechanism(s) of the blood glucose lowering action of benfluorex. Diabetes Metab Rev 9 (suppl 1): 19S-27S, 1993.
14. 14. Bianchi A, Bongers V, Bravenboer B, Erkelens DW: Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients. Diabetes Metab Rev 9 (suppl 1): 19S-27S, 1993.
15. 15. Fromantin M: Effets comparés du Médiator et de la metformine retard dans le traitement du diabète asymptomatique. Institut de Recherches Internationales Servier (registered report Co 780.31.022), 1976.
16. 16. Jaillard J, Riveline B: Etude à double insu de l'efficacité à long-terme du 780 SE (benfluorex) dans le diabète chimique de l'obèse, Prog Med 103: 92-96, 1975.
17. 17. Broussole C, Coste M, Guillon-Metz F, Leutenegger M, Nicolino-Peltier C, Noel G, Richard JL, Roger P, San Marco JL, Schutz D, Simonin R, Vannereau D: Comparaison de l'action antidiabétique du benfluorex et de la metformine. Etude multicentrique coordonnée par M Leutenegger. Sem Hop Paris 64: 3153-3165, 1988.
18. 18. Friedewald WT, Levy RI, Frederickson DS: Estimation of concentration of low density lipoprotein cholesterol in plasma without the use of preparative centrifuge. Clin Chem 18:499-502, 1972.
19. 19. Asmal AC, Leary WPA: Study of the effect of 780 SE (benfluorex) on carbohydrate tolerance and plasma hormone and lipid profile in maturity onset diabetes. Postgrad Med J 51:144-148, 1975.
20. 20. Giustina A, Rocca L, Romanelli G, Zuccato F, Giustina G: Effects of benfluorex on glucose tolerance, metabolism control, beta-cell secretion and peripheral sensitivity to insulin in obese type 2 diabetic patients on a body weight-maintaining diet. Curr Therap Res 45: 33-42, 1989.
21. 21. Bertolini S, Cordera R, Balestri R, Elicio N, Chiodini G, Montagna M, Martini F, Pistocchi G, Corsi A, Gherzi R, Pesenti F, Bonati S, Saturino M, Libianchi S: Etude à long-terme de l'efficacité du benfluorex chez 83 patients hyperlipidémiques (type IIb et IV) présentant une glycémie normale, ou une anomalie de la tolérance au glucose, ou un diabète non insulino-dépendant. Sem Hop Paris 60: 2643-2651, 1984.
22. 22. Arnaud O, Nathan C: Antiobesity and lipid-lowering agents with antidiabetic activity, in: Bailey CJ, Flatt PR, (eds), New Antidiabetic Drugs. London, Smith-Gordon, 1990, pp. 133-142.